Mrna-4157

9 trials 5 recruiting

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

5 Recruiting

4 Completed trials

1 Sponsors

22 Countries

Phase III

Phase II/III

Phase II

Phase III: 3 Phase II/III: 1 Phase II: 5

Oversight events:

4 corrective measures across 4 trials

View oversight register →

Indications tested

Non-small cell lung cancer 2 Bladder cancer 1 Renal cell carcinoma 1

Sponsors using this IMP

Merck Sharp & Dohme LLC 9

All trials

9 total

A clinical study of V940 in people with non-small cell lung cancer (V940-013) Recruiting

2025-520902-37-00 Phase II 4 countries Merck Sharp & Dohme LLC
A clinical study of V940 and pembrolizumab in people with melanoma (V940-012) Recruiting

2024-519605-36-00 Phase II 7 countries Merck Sharp & Dohme LLC
A clinical study of V940 and BCG in people with bladder cancer (V940-011) Recruiting

2024-517335-46-00 Phase II 9 countries Merck Sharp & Dohme LLC
A clinical study of V940 and pembrolizumab to treat lung cancer (V940-009) Recruiting

2023-506327-29-00 Phase III 14 countries Merck Sharp & Dohme LLC
Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting

2023-504923-20-00 Phase III 18 countries Merck Sharp & Dohme LLC
Phase 2 Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma Ended

2023-505177-32-00 Phase II 5 countries Merck Sharp & Dohme LLC
A clinical study of V940 treatment and pembrolizumab in people with bladder cancer (V940-005) Ended

2023-505658-17-00 Phase II 6 countries Merck Sharp & Dohme LLC
Phase 3 Study of V940 and Pembrolizumab in Resected Melanoma Ended

2023-503652-27-00 Phase III 10 countries Merck Sharp & Dohme LLC
Clinical trial of V940 and pembrolizumab in people with resectable locally advanced cutaneous squamous cell carcinoma Ended

2023-505712-37-00 Phase II/III 10 countries Merck Sharp & Dohme LLC

Showing 1–9 of 9 trials

← All drugs A–Z